Stephen M. Nicolai

Stephen M. Nicolai

Counsel
Philadelphia

Email [email protected]​hoganlovells.com

Phone +1 267 675 4642

Fax +1 267 675 4600

Practice groupCorporate & Finance

Stephen Nicolai uses his deep knowledge of the life sciences industry to help clients meet their business goals and identify practical, business-minded solutions to issues that arise in corporate, securities, and commercial matters.

Stephen has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, bought deals, ATMs, RDOs, PIPES, and private placements), alternative financing arrangements (synthetic royalty financings), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including senior executives and boards of directors, on securities, governance, transactional, and a range of other complex issues.

Awards and recognitions

2021

Ones to Watch (Corporate Governance and Compliance Law, Mergers and Acquisitions Law)
The Best Lawyers in America

2021-2022

Ones to Watch (Corporate Governance and Compliance Law, Mergers and Acquisitions Law)
The Best Lawyers in America

Education and admissions

Education

J.D., Villanova University School of Law, magna cum laude, 2011

B.A., West Chester University of Pennsylvania, summa cum laude, 2008

Bar admissions and qualifications

Pennsylvania

New Jersey

Representative experience

Represented a clinical-stage pharmaceutical company in its US$80m initial public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*

Represented a clinical-stage biopharmaceutical company in a US$225m public offering of common stock through a syndicate of underwriters led by J.P. Morgan and Goldman Sachs.*

Regularly advises public companies on a range of corporate governance and securities matters, including fiduciary duties, periodic reports, Section 16 compliance, annual meetings and proxy statements.

Represented a specialty pharmaceutical company in its US$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented OptiNose, Inc. in its US$120m follow-on public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented EyePoint Pharmaceuticals, Inc. in its acquisition of Icon Bioscience, Inc. and accompanying US$60m equity financing with a group of third party investors.

Represented a clinical-stage biotechnology company in its US$80m synthetic royalty financing transaction.

Served as internal legal counsel to the interventional vascular unit of a global health care company.

Represented a clinical-stage oncology company in its reverse merger into a Nasdaq-listed public company.

Represented several life companies in at-the-market equity offerings led by Jefferies, Cowen and Company, Cantor Fitzgerald, and B. Riley FBR.

*Matter handled prior to joining Hogan Lovells.

Loading data